news
New combination treatment enables targeting of non-responsive lung tumours
The newly identified KRAS G12C inhibitor, with SHP2 inhibition, sensitises tumours to immune checkpoint blockade.
List view / Grid view
Oncology
Oncology is a branch of medicine that deals with the prevention, diagnosis and treatment of cancer.
article
Looking beyond traditional oncogenic pathways to break cancer resistance
Drug resistance is the leading cause of poor clinical outcomes for cancer patients undergoing targeted therapies. While current treatments are designed to inhibit targets along established oncogenic signalling cascades, a new, exciting approach is to address non-oncogene-related resistance mechanisms that operate in parallel to the “classic” oncogene pathways. Blocking transcriptional…
news
Anti-PD-1 autoantibody: a biomarker candidate for HCC
The researchers discovered that anti-PD-1 autoantibodies influence the outcome of Atezo/Bev therapy for hepatocellular carcinoma.
article
Initial in vivo validation of novel cancer therapeutics using AI
In this Q&A, Dr Alan D. Roth, CEO of Oxford Drug Design, explains how his AI drug discovery company, which develops novel molecules for use in cancer treatments, has completed the first in vivo validation in its potential first-in-class approach against multiple tumours. A 28-day mouse trial showed clear efficacy…
news
RAD51C variants linked to increased breast and ovarian cancer risk
Researchers have identified over 3,000 harmful genetic changes that could disrupt normal RAD51C function.
news
BCL2 protein linked to metastatic castration-resistant prostate cancer
ICR researchers have discovered that prostate cancer patients with high BCL2 levels have a shorter overall survival rate.
news
New network model efficiently identifies cancer driver genes
The model enables researchers to expand the number of tumours that they can study, increasing their ability to detect novel interactions.
news
NSD2’s role in driving prostate cancer development
This study is the first to demonstrate that NSD2 is foundational to the earliest stage of prostate cancer development.
news
Novel compound for targeted alpha therapy
NpG-D-PSMA has shown great potential for targeted alpha therapy to combat prostate cancer.
article
Women in STEM with Nadine Sprangers
Nadine Sprangers is Vice President, Head of Global Oncology Value, Access and Pricing at Daiichi Sankyo. Holding a PharmD degree and two Master’s Degrees, she leads a team of 50 people responsible for setting the global strategic framework for Pricing, Reimbursement, and Access (PRA), Health Economics and Outcome Research (HEOR),…
news
Pancreatic cancer suppressed by humanised anti-CKAP4 antibody
The humanised antibody, Hv1Lt1, showed promising results in pancreatic cancer mouse models.
article
Advancing CAR-T therapy: how CD5 modulation is shaping cancer treatment
Vittoria Biotherapeutics is pioneering a novel form of CAR-T therapy for T-cell lymphoma using CRISPR gene editing. Here, co-founders Nicholas Siciliano and Marco Ruella explain how their approach promises to overcome tumour resistance, while also offering hope for new ways to treat solid cancers.
article
Patient-centred oncology: transforming drug development
As deeper understanding of disease makes the development and commercialisation of oncology drugs more complex, developers are under more pressure than ever to deliver value-based treatments. In this article, Rebecca Goldstein, Senior Principal, Strategic Consulting at Envision Pharma Group, explores anchoring a programme to patient experience as a solution.
news
Ketogenic diet and a new cancer drug starves pancreatic cells
The discovery that eFT508 blocks eIF4E and the ketogenic pathway could provide the foundation for personalised therapies.
news
Largest multi-omics study of colorectal cancer to date
Five distinct CRC prognostic subtypes were identified, which could revolutionise the way CRC is diagnosed and treated.
